Format

Send to

Choose Destination
Thromb Res. 2012 Mar;129(3):388-91. doi: 10.1016/j.thromres.2011.11.008. Epub 2011 Dec 2.

Old and new heparins.

Author information

1
Dept. Angiology and Blood Coagulation Marino Golinelli, University Hospital S. Orsola-Malpighi, Bologna, Italy. benilde.cosmi@unibo.it

Abstract

Heparin is an effective, relatively safe, inexpensive parenteral antithrombotic agent widely used in the prevention and treatment of thromboembolic disorders, but it has several limitations such as the marked intra- and inter-patient variability in its anticoagulant response, its poor bioavailability at low doses and its relatively narrow risk to benefit ratio. Low molecular weight heparins ( LMWHs), ultra LMWHs and synthetic pentasaccharides have been developed from heparin to overcome its limitations. The characteristics of these compounds are reviewed along with the description of their approved clinical uses.

PMID:
22137740
DOI:
10.1016/j.thromres.2011.11.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center